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ABSTRACT 
Immune driven resistance mechanisms are the prevailing host defense strategy against 
infection. In contrast, disease tolerance mechanisms limit disease severity by preventing 
tissue damage or ameliorating tissue function without interfering with pathogen load. 
Here we propose that tissue damage control underlies many of the protective effects of 
disease tolerance. We explore the mechanisms of cellular adaptation that underlie tissue 
damage control in response to infection as well as sterile inflammation, integrating both 
stress and damage responses. Finally, we discuss the potential impact of targeting these 
mechanisms in the treatment of disease. 
 
INTRODUCTION 
Immunity refers to the inherent ability of any given organism to protect itself from disease 
and more specifically from infectious diseases. The immune system is part of an 
evolutionarily conserved host defense strategy against infection that recognizes, 
destroys and/or expels invading pathogens. Host resistance to infection refers to this 
immune-driven defense strategy, which carries a negative impact on pathogens. This is 
distinct from antimicrobial resistance, which refers to the pathogen’s capacity to evolve 
towards becoming refractory to the detrimental effects imposed by host resistance 
mechanisms or by antimicrobial agents. 
It is widely accepted that immune-driven resistance mechanisms are the prevailing, if 
not the only, host defense strategy against infections. This notion is strongly supported 
by the overwhelming success of medical interventions targeting resistance mechanisms, 
in terms of reducing the global burden imposed by infectious diseases on mankind1. This 
is illustrated by vaccination, where pre-emptive induction of immune-driven host 
resistance mechanisms provides robust and often long-lasting protection against 
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infectious diseases. Another related and highly successful therapeutic approach consists 
in the use of antimicrobial drugs, e.g. antibiotics, which can be perceived as providing 
pharmacologic-driven resistance as the means to limit the severity of infectious 
diseases.  
In some instances however, immune- and/or pharmacologic-driven resistance 
mechanisms are not sufficient per se to prevent morbidity and/or mortality associated 
with infectious diseases, regardless of their capacity to exert a negative impact on 
pathogens. Moreover, microorganisms can evolve resistance mechanisms against host 
immunity2 as well as against antimicrobial drugs and produce compounds3 that increase 
their virulence2. These factors may in part explain why in some cases therapeutic 
approaches targeting resistance mechanisms fail to overcome the morbidity and 
mortality of infectious diseases such as: i) severe forms of malaria associated with 
Plasmodium infection, i.e. 600,000 deaths/year4, ii) severe sepsis associated with 
polymicrobial infections, i.e. 750,000 cases/year in the US alone5 or iii) respiratory 
infections such as pneumonia, associated with influenza virus infections, i.e. 500,000 
deaths/year6, among others. We will argue that in these and probably other cases, a 
second host defense strategy may play a major role in limiting disease severity, namely, 
disease tolerance7-9. 
Immune-driven resistance mechanisms likely co-evolved with disease tolerance 
mechanisms as genetically distinct defense strategies required to limit the severity of 
infectious diseases. In contrast to host resistance, disease tolerance mechanisms limit 
disease severity without affecting the host’s pathogen load7-9, by protecting the infected 
host from tissue damage (Box 1&2). Here we propose that tissue damage control is a 
prevailing mechanism underlying the protective effects of disease tolerance. We explore 
the mechanisms underlying tissue damage control, and discuss the potential impact of 
targeting such mechanisms in the treatment of infectious diseases and possibly other 
immune mediated inflammatory conditions as well. 
 
TISSUE DAMAGE CONTROL AND DISEASE TOLERANCE 
We will refer to cells and/or soluble molecules contributing to host resistance 
mechanisms as the host’s immune system (Fig.1). Cells and/or soluble molecules 
involved in maintaining the integrity of epithelial barriers have a dual protective effect 
against pathogens, i.e. to provide a physical barrier that prevents pathogen systemic 
access and to modulate microbial communities at the epithelial interface via the 
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production of anti-microbial peptides, among other molecules10 (Fig.1). All other host 
cells and/or soluble molecules that do not exert a negative impact on pathogens will be 
referred hereby as the host´s parenchyma (Fig.1). While parenchyma cells, tissues and 
organs do not contribute directly to resistance mechanisms, they are a critical 
component in maintenance of homeostasis, i.e. health11,12. Thus, impaired parenchyma 
function likely underlies the disruption of homeostasis associated with the pathogenesis 
of infectious diseases. 
The host´s immune system drives resistance to infection via a series of mechanisms 
that rely initially on pathogen sensing via cognate binding of pathogen associated 
molecular patterns (PAMP) by host pattern recognition receptors (PRR)13. In addition, 
other classes of sensors may recognize molecular patterns associated with pathogen’s 
effector activities rather than the pathogen itself, i.e. the guard hypothesis14 (Fig.1). This 
hypothesis was raised initially in the context of host-pathogen interactions in plants, in 
which resistance genes were found to protect the infected host from disease caused by 
virulence genes encoded by pathogens. The initial assumption was that the products of 
resistance genes would interact directly and neutralize virulence factors. It became 
apparent however, that resistance genes also act as a PRR, recognizing virulence 
factors and activating immune-driven resistance mechanisms14,15. An alternative 
explanation, i.e. the guard hypothesis, proposes that the products of host resistance 
genes interact physically with host proteins, once these are targeted by virulence 
factors14,15. This hypothesis is supported by the finding that host resistance genes 
encode a family of proteins containing leucine-rich repeats (LRR), which are typically 
involved in protein-protein interactions. Moreover, these were shown to interact 
physically with host proteins modified posttranslationally by virulence factors to prevent 
disease severity14,15. The evolutionary conserved nature of these resistance genes 
suggests that a similar defense mechanism may be operational in animals14,16 
Pathogen sensors are essential to activate innate and adaptive immune 
responses17,18, driving the effector phase of host resistance to infection13. Host 
resistance mechanisms act in a pathogen-class specific manner destroying certain 
classes of pathogens, i.e. bacteria, viruses, fungi and protozoan parasites while 
expelling others, i.e. helminthes. 
Pathogens also express toxins that can elicit varying levels of stress and dysfunction 
to host cells, tissues and organs, eventually leading to programmed cell death, tissue 
damage and organ dysfunction. These include pore-forming toxins that can compromise 
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the integrity of plasma membranes as well as intracellular membranes, disrupting 
cellular homeostasis19. Toxins and other virulence factors are perceived as a central 
mechanism of pathogenicity associated with infectious diseases (Fig.1). This pathogenic 
effect is countered essentially via host resistance mechanisms that reduce pathogen 
load and limit the damaging effects of the associated toxins and virulence factors (Fig.1). 
However, resistance mechanisms per se can impose varying levels of stress, 
dysfunction and eventually damage to the host parenchyma. This phenomenon referred 
as immunopathology, plays a central role in the pathogenesis of many infectious 
diseases (Fig.1)7-9. Of note, not all resistance mechanisms are potentially damaging to 
the host, with some having low if any associated toxicity, e.g. anti-microbial peptides, 
while others are potentially highly damaging, e.g. hypochlorous acid produced by 
activated polymorphonuclear (PMN) cells. 
Depending on the extent of damage imposed to host cells and tissues by microbial 
toxins and/or host resistance mechanisms, desequestration of intracellular 
damage-associated molecular patterns, e.g. heat shock proteins (HSP), adenosine 
triphosphate (ATP), high mobility group box 1 protein (HMGB1), mitochondrial DNA, 
hemoglobin or heme, can occur and engage host PRR20. This phenomenon, referred as 
sterile inflammation can reinforce resistance mechanisms but also immunopathology20,21.  
While host resistance mechanisms are central to clear invading pathogens, 
controlling the severity of infectious diseases requires an additional host defense 
strategy that limits the extent of tissue damage imposed during infection, a protective 
mechanism referred as disease tolerance (Box 1&2; Fig.1)7-9. This requirement for a tight 
coupling of host resistance mechanisms to an additional protective strategy enforcing 
disease tolerance is well illustrated for the regulation of host iron metabolism during 
infection (Box 3).  It is worth noting that disease tolerance describes a biological 
phenomenon quite distinct from immunological tolerance, which has as a hallmark the 
protection of self tissues from immune attack. While the two may be linked functionally, 
for example in their ability to limit tissue damage, they act via distinct effector 
mechanisms. 
We posit that disease tolerance relies on a number of cellular and systemic adaptive 
responses that protect host parenchyma tissues from stress, dysfunction and/or 
damage, and will refer to these protective mechanisms as tissue damage control (Fig.1). 
In contrast to host resistance mechanisms, tissue damage control limits host disease 
severity without interfering with pathogen load (Fig.1)7-9. This countervailing protective 
 5 
response should be required to limit the pathogenic effect associated not only with toxins 
expressed by pathogens but also with some potentially damaging host resistance 
mechanisms.  Thus, tissue damage control acts as an inherent component of host 
defense against infection, required to decouple potentially deleterious immune-driven 
resistance mechanisms from disease severity. 
One should consider that when tissue damage control mechanisms operate on cells 
of the host immune system, these can act in a immunoregulatory manner22,23 that 
impacts on host resistance mechanisms (Fig.1)24. Moreover, when exerted in epithelial 
cells, tissue damage control should enforce barrier function and thus prevent pathogen 
access to host tissues (Fig.1)10. This is in keeping with the notion that tissue damage 
control is an integral component of host defense mechanisms against infection, which 
regulates not only disease tolerance but also resistance and barrier function 
mechanisms when acting on parenchyma, immune cells or barrier epithelial cells, 
respectively. 
Tissue damage control can be enforced via different mechanisms including: i) 
neutralization of toxins and other virulence factors, ii) immunoregulatory mechanisms 
limiting the damaging effects of host resistance mechanisms and/or iii) cellular and 
systemic adaptive responses limiting the deleterious effects associated with different 
forms of stress and damage imposed by pathogens and/or host resistance mechanisms 
(Fig.1). Failure of any of these regulatory mechanisms to prevent tissue damage is 
expected to exacerbate stress, dysfunction and/or tissue damage and as such the 
severity of infectious diseases, presumably without interfering with pathogen load 
(Fig.1). We will focus in the next sections on the molecular basis of cellular and systemic 
adaptive responses limiting tissue damage imposed during infection, i.e. tissue damage 
control. 
 
ADAPTIVE RESPONSES UNDERLYING TISSUE DAMAGE CONTROL 
Tissue damage control is regulated by a number of evolutionary conserved adaptive 
responses acting in a cell autonomous and systemic level to preserve the functional 
integrity of the host tissues7,25. We will discriminate two types of adaptive responses, 
namely stress-responses and damage-responses. This distinction is based on two 
criteria: 1) the sensors used to activate the corresponding adaptive responses, and 2) 
their biologic outputs. Stress-responses are triggered by sensors that respond to 
environmental cues such as those related to variations of oxygen tension, redox status, 
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osmolarity, metabolite concentration, toxins, etc (Fig.2). Stress-sensors and the ensuing 
responses can in principle be triggered in the absence of cellular damage. These aim 
essentially at maintaining cellular function, while preventing different forms of stress from 
causing cellular damage. This occurs via activation of specific stress-responsive 
programs, which provide metabolic adaptation to the environmental changes driving 
different forms of stress while reducing, whenever possible, those forms of stress. 
Damage-responses on the other hand are triggered by sensors that respond to different 
forms of cellular damage. These include damage to macromolecules, i.e. DNA, proteins 
or lipids and to organelles, i.e. mitochondria, endoplasmic reticulum (ER), Golgi 
apparatus or lysosomes. Damage-sensors and their issuing responses are triggered in 
the context of cellular stress - the underlying cause of damage - but in contrast to 
stress-responses, they aim essentially at maintaining cellular function and repairing 
ongoing macromolecular and/or organelle damage. 
 Assuming that different classes of pathogens, i.e. viruses, fungi, bacteria, 
protozoan and eukaryotic parasites, might elicit distinct forms of stress and damage, the 
sensors for those forms of stress and damage and their corresponding responses should 
report on those classes of pathogens, a concept originally proposed by Ruslan 
Medzhitov in discussions at scientific conferences. This suggests as well that stress- and 
damage-responses are functionally integrated within inflammatory responses, likely fine-
tuning host immunity to specific classes of pathogens12. In keeping with this notion, 
signal transduction pathways triggered by PRR or associated with immunoregulatory 
mechanisms exerted by specific immune cell types and/or involving interleukins can 
modulate different stress- and damage-responses, and vice versa and as such regulate 
tissue damage control and disease tolerance. While this added level of complexity 
should not be ignored, here we focus instead on the mechanisms through which tissue 
damage control impacts on defense against disease. 
 
STRESS-RESPONSES AND TISSUE DAMAGE CONTROL 
Stress-responses emerged at an early stage of evolution as the means to provide 
ancestral forms of life with the possibility of adaptation to environmental changes25-27. In 
general, such environmental changes are related to essential components of 
homeostasis, such as i) oxygen tension ii) cellular redox iii) osmolarity and iv) glucose or 
ATP/ADP cellular concentrations, disturbance of which leads to, respectively, hyperoxia 
or hypoxia, oxidative stress, osmotic stress and metabolic stress  (Fig.2). 
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 The common outcome of stress-responses is metabolic adaptation, which enables 
the maintenance of cellular, tissue and organ function under different forms of stress25. 
Metabolic adaptation aims at preserving core cellular functions at the expense of 
accessory ones, while minimizing macromolecular and organelle damage25-27. This is 
achieved via the expression of a number of immediate-early responsive genes coupled 
to broad inhibition of protein synthesis28, repressing non-essential gene functions29. An 
illustrative rather than comprehensive overview of different stress-responses potentially 
regulating tissue damage control is provided in Fig.3. 
 Systemic spreading of pathogens from the initial site of infection is countered by an 
immediate host response characterized by the activation of the clotting cascade 
associated with platelet activation/aggregation and recruitment of activated PMN and 
monocyte/macrophages (Mø). One of the “trade offs” of this defense strategy is local 
deregulation of microvascular circulation, eventually leading to hypoxia, which 
depending on the tissue can have more or less severe pathologic consequences7. 
Hypoxia triggers an evolutionarily conserved stress-response regulated by the 
transcription factor hypoxia-inducible factor 1 alpha (HIF-1α)(Fig.3)30.  When activated in 
immune cells, HIF-1α can promote resistance to infection (reviewed in32,33). In some 
instances, activation of HIF-1α in immune cells can compromise disease tolerance, as 
suggested by the observation that HIF-1α deletion in myeloid cells exacerbates lethality 
from endotoxic shock in mice31. Whether adaptive responses to hypoxia in parenchyma 
tissues, such as orchestrated by HIF-1α, promote tissue damage control and disease 
tolerance remains to be tested.  
Resistance mechanisms often rely on targeting pathogens for oxidative damage via 
PMN cell and Mø activation34. The “trade-off” of this defense strategy includes oxidative 
stress imposed on host tissues, possibly leading to tissue damage, organ dysfunction 
and disease. This is likely counteracted by an adaptive cellular response regulated by 
the evolutionarily conserved transcription factor nuclear factor-erythroid 2-related factor 
2 (NRF2)35,36. Activation of NRF2 provides tissue damage control and disease tolerance 
to malaria caused by Plasmodium infection37,38 and presumably to sepsis caused by 
polymicrobial infections in mice39. When activated in cellular components of host 
immunity, NRF2 modulates resistance to infection, as demonstrated for Salmonella 
infection in mice40 (Box.3). 
Some forms of stress associated with infection can decrease mitochondrial ATP 
output, reducing cellular ATP availability. This is sensed by the infected host via the 
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evolutionarily conserved AMP-activated protein kinase (AMPK), which adjusts cellular 
metabolism to available energy (Fig.3)41. While it is likely that when activated in the host 
parenchyma this adaptive response should confer some level of tissue damage control 
and disease tolerance, this remains to be established. Expression of AMPK in immune 
cells exerts immunoregulatory effects that modulate resistance mechanisms22,23.  
Infection is often associated with local or systemic “growth factor” deprivation, 
whether associated or not to oxidative and metabolic stress. This is sensed by the 
infected host via activation of the evolutionarily conserved Forkhead box O (FOXO) 
family of transcription factors42 (Fig.3). Activation of FOXO during Mycobacterium 
infection in flies is essential to provide metabolic adaptation, e.g. regulation of glycogen 
and triglyceride synthesis, and to limit host disease severity, irrespectively of pathogen 
load43. Thus, FOXO regulates a stress-responsive program that confers disease 
tolerance to infection in flies8. Whether the same is true in mammals remains to be 
tested. Moreover, when activated in cellular components of the host immune system, 
FOXO family members also exert immunoregulatory effects that can impact on 
resistance mechanisms22,23.  
Maintenance of cellular osmolarity is a central component of homeostasis and 
perturbations of osmolarity associated with systemic infections are probably sensed and 
counteracted by osmoregulatory stress-responses, which provide systemic as well 
cellular adaptation to higher or lower than physiologic osmolarity44,45 (Fig.3). These 
stress-responses can act both systemically and in a cell autonomous manner44,45, 
presumably contributing to tissue damage control and disease tolerance, although this 
remains to be established. 
Another stress-response possibly regulating disease tolerance relies on the 
recognition of exogenous and/or endogenous ligands by the evolutionary conserved 
ligand-activated transcription factor aryl hydrocarbon receptor (AhR), best known for its 
involvement in orchestrating a stress-response to xenobiotics46. Several studies have 
shown that activation of this stress-response acts in a immunoregulatory manner that 
maintains barrier tissue function and limits the pathogenesis of immune mediated 
inflammatory conditions (reviewed in47). A recent study, published while this review was 
in preparation, proposes that activation of AhR by L-kynurenine, an endogenous 
intermediate product of the host tryptophan catabolism, confers disease tolerance to 
bacterial infections48. 
 Microbial toxins, such as bacterial pore forming toxins19, are another form of stress, 
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sensed via several host stress sensors including those belonging to the Nod like 
receptor protein (NLRP) family19,49. Activation of NLRP3 by pore forming toxins triggers 
interleukin (IL)-1b secretion, a pro-inflammatory cytokine that activates the 
stress-responsive p38 MAPK and the c-Jun N-terminal kinase (JNK) signal transduction 
pathways, which are protective against pore forming toxins50. Presumably, 
osmoregulatory stress-responses are also involved in adaptive responses to pore 
forming toxins, given that these can disrupt cellular osmolarity50. 
In some cases stress-responses are maladaptive, that is, they fail per se to provide 
sufficient level of metabolic adaptation to different forms of stress, allowing therefore the 
accumulation of macromolecular and organelle damage in cells. This is sensed and 
countered by damage-responses (Fig.2). 
 
DAMAGE-RESPONSES AND TISSUE DAMAGE CONTROL 
Cells have distinct sensors that trigger specific damage-responses associated with 
different types of cellular damage. These share as a common biologic output repair of 
macromolecular and/or organelle damage, aiming at maintenance of cellular function 
within the boundaries of essential outputs and at the expense of accessory ones. An 
illustrative rather than comprehensive overview of damage-responses possibly involved 
in tissue damage control is provided (Fig.4). 
Accumulation of misfolded proteins is a form of macromolecular damage associated 
with different forms of stress51. When misfolded proteins accumulate in the cytosol or in 
the ER these trigger two distinct damage-responses, namely the heat shock 
response52,53 and the unfolded protein response (UPR)51,54,55, respectively (Fig.4). The 
hallmarks of these proteotoxic responses are: i) broad suppression of protein synthesis 
and ii) transcriptional up-regulation of a subset of immediate early-responsive genes that 
escape translational repression, and repair protein damage and/or destroy unfolded 
proteins29,51. To what extent the heat shock and the UPR impact the severity of 
infectious diseases is not clear. While the expression of heat shock factor 1 (HSF-1) has 
been associated with some level of host protection against Listeria monocytogenes 
infection56 as well as against endotoxic shock57 in mice, whether this occurs via a 
mechanism involving tissue damage control and disease tolerance remains to be 
established. The UPR on the other hand confers tissue damage control in mice; the 
expression of X-box binding protein 1 (XBP1) by gut epithelial cells is required to sustain 
epithelial barrier integrity and anti-microbial activity, preventing gut epithelial damage 
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and colitis58. Expression of XBP1 also protects Caenorhabditis elegans against 
Pseudomonas aeruginosa infection without interfering with pathogen load59, arguing for 
an evolutionarily conserved role for the UPR in the regulation of tissue damage control in 
barrier epithelia and presumably elsewhere. It is likely that the salutary effects exerted 
by the UPR in gut epithelial cells relate both to protection from damage imposed by host 
resistance mechanisms59 and also by pathogens58, such triggered by bacterial pore 
forming toxins that can disrupt the gut epithelium10,19. 
DNA damage arising from infections60 must be promptly repaired to avoid 
accumulation of mutations and genomic instability, i.e. the hallmarks of tumorogenesis 
and cancer. This notion is in keeping with the growing recognition that a number of 
cancers are directly or indirectly associated with history of infection60. Pharmacologic 
targeting of DNA-damage-responses regulated by the Ser/Thr protein kinase ataxia 
telangiectasia-mutated (ATM)61 provides a robust protective response against severe 
sepsis elicited by polymicrobial infection in mice62 (Fig. 4). This protective effect acts via 
a mechanism that does not interfere with host pathogen load, conferring tissue damage 
control and disease tolerance to sepsis62. More specifically, DNA-damage-responses 
appear to act predominately at the level of the lung epithelium to confer tissue damage 
control, arguing for a central pathologic role exerted by damage to the lung epithelium in 
the pathogenesis of severe sepsis62. Whether ATM and/or other regulators of DNA 
damage-responses act under pathophysiologic conditions to confer tissue damage 
control during different types of infection is likely, but this remains to be established (Fig. 
4). 
Lipid damage is another form of macromolecular damage associated with different 
types of stress, including lipid peroxidation driven by a self-propagating oxidative 
chain-reaction catalyzed by divalent metals such as iron contained inside the lipophilic 
ring of heme63. Lipid peroxidation can impair membrane functions and promote tissue 
damage, compromising disease tolerance, as illustrated for influenza virus infection in 
mice64.  Presumably effector mechanisms that restrain lipid peroxidation, such as for 
example mediated by glutathione peroxidase 4 (GPX4)65 or by the lipophilic antioxidant 
bilirubin66 (reviewed in67), should promote tissue damage control and in turn disease 
tolerance, but this remains to be established. 
Autophagy is an evolutionarily conserved damage-response triggered by organelle 
damage driven by different forms of stress including redox and metabolic stress, hypoxia 
or protein unfolding as well as driven by PRR signaling (Fig. 4) (reviewed in68). Damaged 
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organelles are captured by the vesicular system and fused to lysosomes, initiating their 
degradation while promoting recycling of their components. Autophagy and its 
manipulation by pathogens modulates host resistance mechanisms68. More recently 
autophagy has also been shown to modulate tissue damage control and disease 
tolerance, as illustrated in the context of polymicrobial infection in mice62. Briefly, 
pharmacologic induction of DNA-damage response by anthracyclines, a group of 
chemotherapeutic agents that activate DNA damage-responses involving ATM, provides 
robust protection against severe sepsis in mice62. This salutary effect acts via a 
mechanism involving two components of the autophagy damage response, namely the 
autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) and the 
autophagy-related protein 7 (Atg7)62. Specific inhibition of Atg7 in the lung is sufficient to 
impair the protective effect of anthracyclines while Atg7 overexpression in the lung is 
protective against severe sepsis62. This argues strongly for the notion of autophagy 
providing tissue damage control in parenchyma tissues, i.e. the lung epithelium, and 
conferring disease tolerance to sepsis.  
 When damage-responses are maladaptive, that is, fail to provide a sufficient level of 
damage repair to enforce tissue damage control, the default outcome is programmed 
cell death leading eventually to irreversible tissue damage, organ dysfunction and 
severe disease (Fig.2 and Box 3). We propose that the pathogenesis of infectious 
diseases is regulated to a large extent by the relative capacity of different stress- and/or 
damage-responses to provide metabolic adaptation and damage repair, at sufficient 
levels as to avoid cytotoxicity, tissue damage and disease (Fig.2). While we have argued 
that tissue damage control mechanisms are a central component of disease tolerance, 
this does not exclude other mechanisms from contributing to disease tolerance. One of 
such mechanisms is likely to involve tissue repair via compensatory proliferation of stem 
cells69. 
 Stress- and damage responses must be tightly regulated during infection, so that 
cellular function can be restored to full capacity as soon as the cause of stress and 
damage, i.e. the pathogen, is eliminated by host resistance mechanisms. Moreover, it 
has been argued that in a similar manner to host resistance mechanisms, tissue damage 
control and disease tolerance operate in a pathogen-class specific manner, a notion 
proposed originally by Ruslan Medzhitov in scientific conferences, and demonstrated 
experimentally in the context of protozoan/bacterial70 as well as viral/bacterial 
co-infection71 in mice. This imposes again the existence of a stringent regulatory 
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mechanism controlling stress- and damage-responses that allows for host protection 
against non-overlapping classes of pathogens.  
 
TISSUE DAMAGE CONTROL IN NON-COMMUNICABLE DISEASES 
Stress- and damage-responses also exert protective effects against non-communicable 
diseases in which inflammation or misdirected immunity act as the underlying cause of 
pathology. In keeping with this notion the stress-responsive program regulated by NRF2 
is protective against organ ischemia and reperfusion injury (IRI), via a mechanism 
involving the expression of several effector genes, including the stress-responsive 
enzyme heme oxygenase-1 (HO-1, encoded by the HMOX1 gene)72 and the iron 
sequestering protein ferritin heart/heavy chain (encoded by the FTH gene)73(Box 3). This 
salutary effect is also observed in the context of heart and brain IRI72, presumably 
limiting the pathogenesis of myocardial infarction and stroke, the two major 
non-communicable diseases in terms of global impact on human morbidity and mortality. 
Other adaptive responses conferring protection against IRI include the metabolic stress-
response regulated by AMPK74 and the UPR75. Moreover ischemic pre-conditioning, a 
hormesis-like protective response against IRI (Box 4)76, acts via a mechanism involving 
HIF-1α30.  Stress-responses regulated by NRF277 and HIF-1α32 also prevent the rejection 
of transplanted organs via a mechanism involving tissue damage control, and driven 
most probably by HO-1 expression72. Transplanted organs can also undergo a 
hormesis-like response76 (Box 4) termed accommodation78, which prevents graft 
rejection via a mechanism involving again the expression of HO-179. 
Autoimmune diseases are another group of non-communicable diseases in which 
stress- and damage-responses can act in a salutary manner. This is illustrated by the 
oxidative stress-response regulated by NRF2, which prevents the onset of diabetes80, 
systemic lupus erythematosus81, rheumatoid arthritis82 and multiple sclerosis83 in murine 
models for these diseases. Damage responses also exert protective effects against 
autoimmune diseases, as illustrated for the UPR in the context of type 1 diabetes, where 
impaired expression of the the UPR components activating transcription factor 6 (ATF6) 
and XBP1 in -cells of the pancreas are associated with disease progression in both 
mice and humans84. Importantly, targeting the UPR pharmacologically in -cells inhibits 
the pathogenesis of experimental type 1 diabetes in mice, a salutary effect associated 
with -cell cytoprotection and reduced inflammatory infiltrates84. The UPR also exerts 
protective effects against autoimmune neuroinflammation, as illustrated in mice for the 
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expression of the UPR component protein kinase RNA-like ER kinase (PERK) in 
olygodendrocytes85.  As referred above, expression of the UPR component XBP1 in 
intestinal epithelial cells inhibits colitis in mice while hypomorphic variants of the human 
XBP1 allele are associated with susceptibility to inflammatory bowel disease58. It is worth 
noticing that the salutary effects exerted by the UPR against the pathogenesis of these 
immune-mediated inflammatory diseases appear to act essentially in parenchyma cells 
in which protein synthesis is overabundant, as illustrated for -cells, oligodendrocyte an 
intestinal epithelial cells, which produce high levels of insulin, myelin and mucins, 
respectively. Whether hormesis-like responses (Box 4)76 involving stress- or damage-
responses confer protection against autoimmunity remains to be established. 
 
THERAPEUTIC TARGETING OF TISSUE DAMAGE CONTROL 
The widespread and often uncontrolled usage of anti-microbial drugs and in particular 
antibiotics, in the treatment of infectious diseases led to the selection of 
multidrug-resistant pathogens1. Targeting tissue damage control and disease tolerance 
might be a major therapeutic option when treating infectious diseases caused by 
multidrug resistant pathogens. This therapeutic approach, referred as supportive 
therapy, is already widely used in severe sepsis, severe forms of malaria, severe 
diarrheal diseases, severe febrile illness as well as fatal hemorrhagic fevers. Presumably 
a more rational development of pharmacologic agents targeting specifically central 
regulators of different stress- or damage-responses, e.g. NRF235, HIF1-32, AMPK or 
ATM62, conferring tissue damage control should be of therapeutic value in the treatment 
of these pathologic conditions. The same rationale can be applied to the treatment of 
non-communicable diseases in which inflammation and/or immunity act as the 
underlying cause of disease. In support of this notion, pharmacologic use of anti-
oxidants confers disease tolerance to Plasmodium infection in mice86,87. Also, activation 
of DNA damage responses and autophagy by anthracyclines - involving ATM, LC3B, 
ATG7 - confers disease tolerance to polymicrobial infections, acting therapeutically 
against severe sepsis in mice62. Pharmacologic administration of amphiregulin, an 
epithelial growth factor family member, confers disease tolerance to bacterial pneumonia 
after influenza virus infection in mice71 and as mentioned above pharmacologic induction 
of the UPR in -cells also provides tissue damage control and mitigates the 
pathogenesis of type-1 diabetes in mice84. These findings argue strongly for the potential 
therapeutic targeting of these stress- and damage-responses outside the specific 
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context of infectious diseases. 
 
CONCLUDING REMARKS 
Vaccination and anti-microbial drugs resulted in global protection of mankind against a 
variety of pathogens. These approaches however, failed to confer robust protection 
against insidious infectious diseases that remain a major cause of morbidity and 
mortality worldwide. Moreover the emergence of a growing number of highly virulent 
multidrug-resistance pathogens compromises the current therapeutic handling of 
infectious diseases. In these cases, disease tolerance may play a major role that is often 
not considered in terms of our understanding of the pathogenesis of infectious diseases 
or their treatment. Therefore, a fuller understanding of disease tolerance and underlying 
mechanisms, including tissue damage control, is of clear basic and clinical relevance. 
A major challenge is to identify and characterize the molecular mechanisms 
regulating disease tolerance to specific classes of pathogens. Assuming that disease 
severity reflects more or less pronounced disruption of homeostasis one should monitor 
in a quantitative manner “homeostatic parameters” as read-outs of disease driven by 
infection. Such “homeostatic parameters” include those related to the functional outputs 
of vital organs essential for maintenance of homeostasis, including the heart/vascular, 
lung, kidney, liver and brain. This approach used in a daily basis clinically should be 
adapted to experimental systems addressing at molecular level the mechanism 
underlying disease tolerance. The expectation is that disease severity will be reflected 
by quantitative variations of those parameters and that mechanisms controlling disease 
tolerance should modulate those parameters within the boundaries of homeostasis, 
without interfering with pathogen load. Another major challenge is the identification and 
characterization of the functional points of integration between immune-driven resistance 
and tissue damage control mechanisms regulating disease tolerance. The prediction is 
that immunoregulatory mechanisms will modulate stress- and damage-responses and 
hence tissue damage control and disease tolerance. It is expected that these endeavors 
will enable further understanding of host-pathogen interactions and the rational targeting 
of disease tolerance mechanisms in the treatment of infectious diseases. 
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BOX 1:  
An historical perspective of disease tolerance: Disease tolerance was first 
recognized as a plant defense strategy against infection88,89, with its original description 
dating back to as early as the end of the XIX century90. The concept was refined by mid 
XX century, as the ability to sustain infection without a concomitant reduction in host 
fitness89. These studies posit that disease tolerance does not rely on reducing host 
pathogen load for preservation of health88 but instead acts via mechanisms that limit 
parenchyma damage89. While the concept of disease tolerance was rapidly expanded to 
different types of infection in plants89, it took over a century to extrapolate this notion 
beyond the plant literature. This was achieved by a series of studies on the immune 
response of Drosophila melanogaster to infection, which revealed that loss of function 
mutations in genes encoding inflammatory cytokines, e.g. the tumor necrosis factor 
(TNF) homolog eiger or in genes controlling metabolic stress-responses, i.e. forkhead 
box transcription factor (FOXO) and AKT (Fig.3) modulate host survival without 
interfering with pathogen load8,9,43. These and other studies revealed the involvement of 
specific genes in the regulation of “endurance” to infection, now referred as disease 
tolerance by analogy to the plant literature8,9, while the same phenomenon is often 
referred to as "resilience" as well91. Contemporary with these studies is the finding that a 
symbiont of flies, i.e. the intracellular bacteria Wolbachia, regulates not only host 
resistance but also disease tolerance to viral infections92. In addition to demonstrating 
that disease tolerance is operational in flies, these studies revealed that host interaction 
with a given microbe can regulate disease tolerance and as such the pathologic impact 
of infection by other pathogens92. Again contemporary to these studies, is the finding 
that disease tolerance also occurs in animals, including worms59 as well as mice86,93. 
Overall, these studies “opened the way” to the cellular and molecular characterization of 
the mechanisms involved in disease tolerance, which have now started to become 
elucidated, and shown to rely on evolutionarily conserved stress- and damage-
responsive programs that adapt and maintain host parenchyma function during infection 
(Fig.3&4). 
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BOX 2:  
Disease tolerance in mammals: Disease tolerance was first demonstrated formally in 
mammals, and interpreted as such, in the context of Plasmodium infection93, the 
causative agent of malaria. Namely, mice from different genetic backgrounds were found 
to develop varying levels of disease severity, irrespectively of their corresponding 
pathogen loads93. This observation and the conceptual framework under which it was 
interpreted were instrumental in extrapolating the notion that genetically encoded 
mechanisms confer disease tolerance mammals93. Contemporary to this study, is the 
finding that the Kcnj8 gene, encoding the ATP-sensitive potassium (KATP) channel Kir6.1, 
is essential for protection against viral infections in mice, without interfering with 
pathogen load94.  
 The cellular and molecular mechanisms regulating tissue damage control and 
disease tolerance remain poorly understood. In the specific context of Plasmodium 
infection93 these have been linked functionally to a evolutionary conserved 
stress-responsive and cytoprotective program that provides metabolic adaptation to 
cellular iron overload87,95. Two effector genes have been functionally implicated, namely 
the heme catabolizing enzyme HO-186,96,97 and the ferritin heart/heavy chain (FTH)87,95. 
These provide a systemic adaptive response to tissue iron overload in the infected host, 
which prevents cytotoxicity and tissue damage caused by the accumulation of iron-heme 
during the blood stage of Plasmodium infection86,96,97. The same stress-responsive 
program is involved in conferring tissue damage control and disease tolerance to severe 
sepsis driven by polymicrobial infection98. 
 Assuming that unfettered cytotoxicity is a common underlying mechanism driving 
tissue damage during infection, stress- and damage-response that confer tissue damage 
control and disease tolerance to infection should protect host parenchyma cells from 
programmed cell death. In support of this notion is the finding that deletion of the RIP 
kinase 3 (RIPK3) gene, a master regulator of programmed cell death by necroptosis99, is 
sufficient per se to confer tissue damage control and disease tolerance to systemic 
polymicrobial infection in mice100. Moreover, deletion of the Birc3 (cIAP2) gene, encoding 
a E3 ubiquitin ligase that suppresses necroptosis, impairs tissue damage control and 
disease tolerance to influenza virus infection in mice101. These findings suggest that 
stress- and damage-responses conferring tissue damage control may target directly or 
indirectly the RIPK1/3-driven necroptosis signal transduction pathway to confer disease 
tolerance or resistance to infection, a hypothesis that remains to be tested. 
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BOX 3:  
Metabolic adaptation to iron overload and disease tolerance. Based on its relative 
abundance and ability to exchange electrons with a number of donor/acceptor molecules 
iron is at the center stage of many vital biological functions. Pathogens rely strictly on 
iron acquisition for the progression of infection, evolving strategies that fuel host iron into 
their own metabolic pathways102. It follows that host strategies that deny pathogen 
access to iron are a central and evolutionarily conserved host resistance 
mechanism95,102,103. This defense strategy relies to a large extent on the expression of: i) 
hepcidin antimicrobial peptide gene (HAMP), a master regulator of systemic iron 
metabolic adaptation during infection that reduces iron acquisition from diet and 
suppresses iron cellular export103, ii) lipocalin-2, a soluble iron chelator encoded by the 
LCN2 gene that prevents extracellular pathogens from accessing iron104 and iii) natural 
resistance associated macrophage protein function (NRAMP-1), an intracellular iron 
transporter encoded by the SLC11A1 gene, that removes iron from phagolysosomes 
and limits iron supply to intracellular pathogens105.  
Systemic regulation of pathogen access to host iron has a major “trade off”, namely, 
host tissue iron overload compromising host parenchyma function95. Moreover, systemic 
disruption of cellular iron export can interrupt iron supply to hemoglobin synthesis and 
erythropoiesis, causing anemia of chronic disease106. Therefore systemic modulation of 
host iron metabolism during infection provides a paradigm for the requirement of an 
integrated host defense strategy in which resistance mechanisms must be coupled to 
tissue damage control as to limit the severity of infectious diseases87,95. This is 
accomplished via metabolic adaptation to tissue iron overload, via a mechanism 
involving the expression of ferritins87,95.  
Ferritins are multimeric nanocage-like structures made of FTH (heavy/heart) and FTL 
(light/liver) chains, that can incorporate up to 4,500 iron atoms in the form of inorganic 
ferrihydrite aggregates107. FTH ferroxidase activity converts reactive iron (Fe2+) into inert 
iron (Fe3+) that does not partake in the production of free radicals via the Fenton 
chemistry95. This anti-oxidant effect confers tissue damage control and disease 
tolerance to infection in mammals87,95 as well as in plants108, arguing for the 
evolutionarily conserved nature of this host defense strategy. 
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BOX 4: 
Overlapping protection, evolution and hormesis. There is an overlapping profile of 
gene expression associated different stress- and damage-responses in evolutionary 
disparate organisms25-27,53. This argues for the involvement of a core number of 
evolutionarily conserved effector genes in the regulation of those stress- and 
damage-responses and as such on the regulation of tissue damage control and disease 
tolerance. Presumably, stress- and damage-responses evolved from ancestral forms of 
life where they provided adaptation to environmental changes26 being co-opted through 
evolution to provide host protection against infection25,27. These ancestral adaptive 
responses preceded most probably those underlying host resistance mechanisms, 
co-evolving thereafter to decouple potentially damaging resistance mechanisms from 
tissue damage and disease severity. This is in keeping with the notion that some host 
resistance mechanisms can per se elicit cellular stress and damage, which in the 
absence of a countervailing protective response would be pathogenic. We propose that 
stress- and damage-responses conferring tissue damage control and disease tolerance 
to infection are required to decouple potentially deleterious resistance mechanisms from 
disease severity. The overlap of signal transduction pathways and profiles of gene 
expression associated with different stress- and damage-responses (Fig.2-4) also 
argues for some level of cross-protection against seemingly unrelated forms of stress 
and damage68. This phenomenon known as hormesis76, is also referred as pre-
conditioning in the context of organ IRI, or energy restriction in the context of ageing as 
well as accommodation in the context of organ transplantation78. The shared principle 
being that sub-toxic forms of stress and/or damage can elicit adaptive responses in cells, 
tissues, organs or organisms that are protective against subsequent exposure to toxic 
levels of the same or unrelated forms of stress and/or damage76. The impact of this 
phenomenon for infectious diseases is supported by the finding that the protective effect 
exerted by sickle hemoglobin against malaria, relies on a hormesis-like effect involving 
the activation of the stress-response regulated by NRF2 and providing tissue damage 
control and disease tolerance to Plasmodium infection97. A similar effect has been 
assigned to the protective effect of nitric oxide against the development of severe 
malaria in mice38. This suggests that targeting hormesis-like mechanisms may be used 
as a strategy induce tissue damage control and disease tolerance to other types of 
infection, a notion supported by the protective effect exerted by pharmacologic targeting 
of the DNA damage-responses against severe sepsis in mice62.  
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FIGURE LEGENDS:  
Figure 1: Tissue damage control in host microbe interactions. Homeostasis is 
governed to a large extent by parenchyma tissues that do not exert a negative impact (-
|) on pathogens. Toxins and other virulence factors expressed by pathogens can elicit 
cellular stress and damage to the host parenchyma (lighting bolt arrow), disrupting 
homeostasis. This is a major driver in the pathogenicity of infectious diseases. 
Recognition of pathogens (PRR/PAMP) activates (->) the host innate and adaptive 
immune response, reducing pathogen load and hence pathogenicity. This defense 
strategy, called host resistance to infection, can have a direct negative impact (-|) on 
host parenchyma (immunopathology) or an indirect negative impact (-|) in combination 
with toxins. This is another major driving force in the pathogenesis of infectious 
diseases. Tissue damage control refers to a protective mechanism that limits the extent 
of stress and damage imposed to host cells by toxins and other virulence factors as well 
as by host resistance mechanisms. When exerted in parenchyma, tissue damage control 
reduces disease severity without interfering with pathogen load, and is said to confer 
disease tolerance to infection. Toxins and virulence factors as well as host resistance 
mechanisms (not depicted in figure) can exert a negative impact (-|) on host epithelial 
cells, disrupting barrier functions. When exerted in host epithelial cells, tissue damage 
control enforces barrier function, contributing to host resistance mechanisms. Toxins and 
virulence factors can also exert a negative impact (-|) on components of the host 
immune system, impairing resistance to infection. Therefore, when exerted in the 
immune system, tissue damage control can act in an immunoregulatory manner and 
modulate resistance mechanisms.  
 
Figure 2: Stress- and damage-responses: Circles indicate signal transduction 
pathways regulating specific gene profiles, as triggered by different sensors represented 
by rectangles. Activation of stress- and damage-responses provides tissue damage 
control and disease tolerance to systemic infections. When stress-responses are 
maladaptive, that is, when these fail to provide sufficient levels of metabolic adaptation 
to different forms of stress, the result is macromolecular, i.e. protein, lipid, DNA, and/or 
organelle damage. This triggers a functionally different set of adaptive responses that 
are no longer aimed at providing metabolic adaptation but instead aim at repairing 
macromolecular and/or organelle damage, i.e. damage repair. Damage responses, act 
presumably as a second layer of tissue damage control to enforce disease tolerance. 
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When damage-responses are maladaptive, that is, fail to provide sufficient 
macromolecular and/or organelle damage repair, the default program is programmed 
cell death, leading to tissue damage, organ dysfunction and eventually to disease.  
 
Figure 3: Stress-response pathways: Stress-responses are controlled by a number of 
master regulators (red rectangles) that provide cellular adaptation to specific forms of 
stress. Hypoxia is sensed by the prolyl hydroxylase (PHD)2, which uses O2 to 
hydroxylate two proline residues in the transcription factor HIF-1α. This promotes the 
recruitment of the E3 ubiquitin ligase von Hippel-Lindau (VHL/Cul3), ubiquitinating 
(green circle; Ub) and targeting HIF-1α for proteolytic degradation by the 26s 
proteasome pathway30. PHD2 activity is inhibited when O2 pressure (pO2) decreases 
bellow physiologic levels, i.e. hypoxia. This releases HIF-1α from VHL, allowing for 
HIF-1α nuclear translocation and binding to DNA hypoxia responsive elements (HRE) in 
the promoter of effector genes regulating metabolic adaptation to hypoxia30. Oxidative 
stress is sensed by the Kelch-like ECH-associated protein 1 (Keap1) that controls the 
activation of the transcription factor NRF2, a member of the Cap’n’collar basic leucine 
zipper family of transcription factors that acts as a master regulator of cellular adaptive 
responses to oxidative stress36. Under homeostasis, Keap1 acts as an ubiquitin E3 
ligase, targeting NRF2 for ubiquitination (green circle; Ub) and proteolytic degradation by 
the 26s proteasome pathway35. Oxidative stress causes several sulfhydryl groups in 
Keap1 to form disulfide bounds, inhibiting its ubiquitin E3 ligase activity and releasing 
NRF2, which associated with small Maf proteins109 and undergoes nuclear translocation, 
binding to the DNA antioxidant responsive elements (ARE) in the promoter of genes 
regulating adaptation to oxidative stress35. Metabolic stress. Cellular AMP, ADP and 
ATP concentrations are maintained at constant levels by different mechanisms 
regulating ATP production in the mitochondria and ATP consumption. Moreover, 
adenylate kinase (ADK) catalyzes the conversion of 2 ADP into ATP + AMP. When 
cellular ATP concentration decreases, ADP to ATP ratio increases displacing the 
reaction catalyzed by adelylate kinase towards ATP and AMP. This is sensed by AMPK, 
which orchestrates a cellular adaptive response promoting catabolic pathways 
generating ATP while switching-off ATP consumption41. Multiple forms of stress can 
be sensed by the evolutionarily conserved Forkhead box O (FOXO) family of 
transcription factors42. Under homeostasis, FOXO activity is suppressed via the 
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insulin-signaling transduction pathway involving PI3K and AKT and promoting sustained 
FOXO binding to 14.3.342. Inhibition of PI3K and AKT is associated with activation of 
upstream stress-activated mitogen activated protein kinases (MAPK), including the Jun 
N-terminal kinase (JNK). These trigger FOXO post-translational modifications (PTM) 
promoting its nuclear translocation and binding to specific DNA motifs in the promoter of 
genes that confer adaptation to multiple forms of stress. Osmotic stress elicits an 
immediate adaptive response modulating cellular volume and intracellular 
concentrations of inorganic ions and macromolecules, via a mechanism involving the 
aquaporin “water channels” (AQP) and solute carrier channels (SLC). Prolonged osmotic 
stress is sensed by the protein kinase A-anchoring protein 13 or Brx45, which activate 
MAPK. These include the p38 MAPK that targets the transcription factor nuclear factor of 
activated T-cells 5 (NFAT5), also know as the tonicity-responsive element binding 
protein (TonEBP). Phosphorylated NFAT5 dimerizes and undergoes nuclear 
translocation binding to DNA osmotic response elements (ORE), in the promoter of 
osmoregulatory genes44. A recent study proposes that activation of the xenobiotic 
stress-response regulated by AhR confers disease tolerance to bacterial infections48 (not 
illustrated). 
 
Figure 4: Damage response pathways. Damage-responses are controlled by a 
number of macromolecular and organelle damage sensors. These activate specific 
genetic programs providing cellular adaptation to different forms of cellular damage. 
Unfolded protein response (UPR). Accumulation of misfolded proteins in the ER lumen 
is sensed by the binding immunoglobulin protein (BiP)/78 kDa glucose-regulated protein 
(GRP-78) chaperone and the inositol requiring protein-1 (IRE1), two master regulators of 
the UPR54,55. Dimerization and release of GRP78, de-repress IRE1 activity55, which 
splices X-box binding protein 1 (XBP1) mRNA, promoting XBP1 translation, nuclear 
translocation and binding to DNA X-box elements in the promoter of effector genes 
regulating the UPR. Binding of GRP-78 to unfolded proteins in the ER lumen also 
triggers the activation of the protein kinase RNA-like ER kinase (PERK) and the 
transcription factor-6 (ATF6). PERK represses mRNA translation55 and activates 
different substrates, including NRF2, which regulates the expression of several effector 
genes that provide disease tolerance to infection. ATF6 also induces the transcription of 
different genes contributing to the UPR, including XBP1. Heat shock response. 
Accumulation of misfolded proteins in the cytoplasm, as a result of cellular exposure to 
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higher than physiologic temperatures, i.e. fever, or other forms of stress associated with 
infection is sensed by heat shock proteins (HSP), e.g. chaperones52. Under 
homeostasis, components of the Hsp90 chaperone family repress the transcription factor 
heat shock factor 1 (HSF1), the master regulator of the heat shock response. Misfolded 
proteins recruit Hsp90. This releases HSF1, which homotrimerizes and undergoes 
nuclear translocation, binding to DNA heat shock elements (HSE) in the promoter of 
different classes of HSP genes. DNA damage. DNA double strand breaks, one of the 
most deleterious forms of DNA damage, are sensed by the Mre11/Rad50/Nbs1 complex, 
which activates ATM, a master regulator of the double stranded DNA damage-
response61. Under homeostasis ATM exists essentially as a homodimer, dissociating 
into active monomers in response to DNA double strand breaks61. ATM orchestrates an 
adaptive cellular response involving substrate proteins that regulate cell cycle 
progression, metabolic adaptation or programmed cell death61. Autophagy relies on the 
cellular vesicular system initiated by a process of nucleation of damaged organelles, 
elongation and maturation leading to lysosome (Lys) fusion, and allowing for degradation 
and recycling of their components68.  
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 ABBREVIATION: 
ADK: adenylate kinase; AMPK: AMP-activated protein kinase; AQP: aquaporin; ARE: 
antioxidant responsive elements; ATF6: activating transcription factor-6; ATM: ataxia-
telangiectasia mutated; CBP: CREB binding protein; CO: Carbon Monoxide; CREB: 
cAMP response element-binding protein; ER: endoplasmic reticulum; Fe: iron; FOXO: 
Forkhead box O; FTH: ferritin heart/heavy chain; FTL: ferritin liver/light chain; GRP-78: 
glucose-regulated protein; HAMP: hepcidin antimicrobial peptide gene; HIF-1α: hypoxia-
inducible factor 1 alpha; HO-1: HMOX1/heme oxygnease-1; HRE: hypoxia responsive 
elements; HSE: heat shock elements; HSF1: heat shock factor 1; HSP: heat shock 
proteins; IRE1: inositol requiring protein-1 ; IRI: ischemia and reperfusion injury; JNK: 
Jun N-terminal kinase; Keap1: Kelch-like ECH-associated protein 1; MAPK: mitogen 
activated protein kinases; NFAT5: nuclear factor of activated T-cells 5; NRAMP-1 natural 
resistance associated macrophage protein function; NRF2: nuclear factor-erythroid 2-
related factor 2; ORE: osmotic response elements; PAMP: pathogen associated 
molecular patterns; PERK: protein kinase RNA–like endoplasmic reticulum kinase; 
PHD2: prolyl hydroxylase 2; PRR: pattern recognition receptors; PTM: post-translational 
modifications; HSP: small heat shock proteins; SLC: solute carrier channels; TNF : tumor 
necrosis factor; TonEBP: tonicity-responsive element binding protein; Ub: ubiquitinating; 
UPR: unfolded protein response; VHL/Cul3: von Hippel-Lindau; XBP1: X-box binding 
protein 1. 
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